Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01506531 · ClinicalTrials.gov registry record · NA
Silo Versus Primary Closure for Gastroschisis
A NA study, sponsored by Children's Mercy Hospital Kansas City.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT01506531: Completed NA study, sponsored by Children's Mercy Hospital Kansas City.
NCT01506531 is a NA study that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01506531, a NA study, has completed, sponsored by Children's Mercy Hospital Kansas City.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
The objective of this study is to scientifically evaluate two different closure strategies for gastroschisis to determine if there is a difference in the two approaches.
Primary Outcome
The length of time required for meeting discharge criteria
Interventions
- PROCEDURE silo for gastroschisis
- PROCEDURE Primary closure of gastroschisis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2011-08 |
| Est. Completion | 2018-04 |
| Phase | NA |
What the finished NCT01506531 record still lists
NCT01506531 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which silo for gastroschisis is the first listed.
NCT01506531 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01506531 about?
NCT01506531 is a clinical study titled "Silo Versus Primary Closure for Gastroschisis". The objective of this study is to scientifically evaluate two different closure strategies for gastroschisis to determine if there is a difference in the two approaches.
What is the current status of trial NCT01506531?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2011-08. Estimated completion is 2018-04.
What interventions are being tested in trial NCT01506531?
The interventions under investigation include: silo for gastroschisis (PROCEDURE), Primary closure of gastroschisis (PROCEDURE).
Who is sponsoring clinical trial NCT01506531?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01506531's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia